Académique Documents
Professionnel Documents
Culture Documents
Clinical Pharmacology
3
Michaelis-Menten kinetics (2)
As larger amounts of substrate
are added to a reaction, the
available enzyme binding sites
become filled to the limit of
Vmax
Beyond this limit the enzyme is From Enzyme kinetics Notes
saturated with substrate and
the reaction rate ceases to
increase
Saturation curve for an enzyme
rxn showing relation between
substrate concentration and
reaction rate 4
Lineweaver-Burk plot
(the inverse of M-M plots)
y-intercept , Vmax
5
Enzyme inhibition (1)
Reversible competitive inhibitors cross
each other competitively, whereas
noncompetitive inhibitors do not
REMEMBER
increase y-intercept means decrease Vmax
6
Enzyme inhibition(2) Table
Competitive Competitive Noncompetitive
inhibitors, inhibitors, inhibitors
reversible irreversible
7
Pharmacology Terminology
Most drugs evoke effects by interacting with receptors
Affinity
Efficacy [pharmacologic] or
(synonym) Intrinsic activity [molecular]
Agonists
Mimic physiologic activation
Have both high affinity and efficacy
Antagonists
Block actions of neurotransmitters or agonists
Have high affinity, but no efficacy
Often used as pharmacologic reversal agents 8
What are the differences between competitive
and noncompetitive inhibitors? (1)
Competitive inhibitors (antagonist) bind to same active site of an
enzyme (receptor) as substrate (ligand/drug) of interest
In competitive inhibition (antagonism) , the enzyme (receptor) is
bound to either substrate (drug/agonist) or inhibitor (antagonist)
at any given point
This is because inhibitor (antagonist) closely resembles
substrate
Competitive inhibition (antagonist) can be overcome by
overwhelming the system with increasing concentrations of
substrate (agonist) , which compete with inhibitor (antagonist) for
active site of catalytic enzyme (receptor)
9
What are the differences between competitive and
noncompetitive inhibitors? (2)
On the other hand,
Noncompetitive inhibitors (antagonist) bind to alternate sites of
enzyme (receptor) other than the active binding site
Do not resemble substrate (ligand/drug)
binding of noncompetitive inhibitor to enzyme (receptor) of interest
distorts enzyme (receptor) such that it can no longer bind to substrate
(ligand/drug)
Noncompetitive inhibition (antagonism) is often irreversible and
cannot be overcome by saturating system with increasing
concentrations of substrate (ligand/drug)
10
Receptor binding:
Agonist with Competitive antagonist
Effect
Shifts curve right ( potency), no
change in efficacy
Can be overcome by the
concentration of agonist substrate
Example
Diazepam (agonist) + flumazenil
(competitive antagonist) on GABA
receptor
11
Receptor binding:
Agonist with Non-Competitive antagonist
Effect
Shifts curve down (efficacy)
Cannot be overcome by agonist substrate
concentration
Example
Norepinephrine (agonist) +
Phenoxybenzamine (noncompetitive
antagonist) on α-receptors
12
Receptor binding:
Agonist with Partial Agonist (alone)
Effect
• Acts at same site as full agonist, but
with lower maximal effect ( efficacy)
• Potency is an independent variable
Example
• Morphine (full agonist) vs.
buprenorphine (partial agonist) at
opioid μ-receptors
13
Efficacy vs. potency
Efficacy RELATIVE EFFICACY
14
Efficacy vs. potency (2)
Potency RELATIVE POTENCY
15
Ligand-receptor binding curves
A. Linear B. Semilogarithmic
A. Linear graphs of drug-receptor binding for two drugs with different values of Kd.
B. Semilogarithmic graphs of the same drug-receptor binding. Kd = equilibrium dissociation constant for a
given drug-receptor interaction. A lower Kd indicates a tighter drug-receptor interaction (higher affinity). Drug
A, which has the lower Kd, will bind a higher proportion of total receptors than Drug B at any given drug
concentration. Notice that Kd corresponds to the ligand concentration [L] at which 50% of receptors are bound
(occupied) by ligand. [L] is concentration of free (unbound) ligand (drug), [LR] is concentration of ligand-
receptor complexes, and [Ro] is total concentration of occupied and unoccupied receptors. Thus, [LR] /[R0] is
the fractional occupancy of receptors, or fraction of total receptors that are occupied (bound) by ligand.
Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy
16
Cairo CW, Simon JB, Golan DE. (Eds.); LLW 2012, Pgs. 17-27
Graded dose-response curves
A. Linear B. Semilogarithmic
Therapeutic window is
measure of clinical drug
effectiveness for a patient
Therapeutic Index = TD50 / ED50
Safer drugs have higher TI values
Drugs with lower TI values include digoxin, lithium, theophylline, and
warfarin
LD50 (lethal median dose) often replaces TD50 in animal studies 18
19
Further study:
eNotes: GP- General Principles of Drug Action
20